Anzeige
Mehr »
Dienstag, 10.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
267 Leser
Artikel bewerten:
(1)

Baker Tilly: Strategic Stewardship: Navigating Compliance and Corporate Responsibility in Life Sciences

CHICAGO, IL / ACCESS Newswire / January 23, 2026 / Authored by Baker Tilly's Mark Scallon

Life sciences companies must work to sustain healthcare advancement and development while uncertainty around National Institute of Health (NIH) funding and other administrative changes stress the industry. Gaps in funding may be filled by an increase in stewardship activities, such as:

  • Medical Education Grants

  • Research Grants

  • Investigator-Initiated Studies (IIS) / Investigator-Initiate Trails (IIT)

  • Charitable Contributions

  • Social programs supporting research and development (R&D)

While these initiatives are critical to progress, the expected surge in funding requests amplifies compliance risks. In this article, we explore strategies for balancing ethical engagement with meaningful impact and why automation is key to managing this evolving landscape.

Stewardship

Stewardship is the careful and responsible management of resources entrusted to your case, including natural resources, assets or even time and talents. It means acting as a caretaker for assets you do not own, with the goal of protecting and preserving them for the future.

The funding landscape: A perfect storm

Recent policy shifts have dramatically altered the research funding environment:

  • Cancelled grants: In the last year, more than 1,800 active NIH research grants have been terminated, reducing awarded funds by approximately $8 billion compared to 2024.

  • Targeted research cuts: Programs focused on diversity, equity and inclusion (DEI), environmental harms and critical health areas-including sickle cell disease, HIV/AIDS and mental health-have been affected by these cuts.

  • Projected budget reductions: For 2026, the administration has proposed slashing the NIH budget by 43%, an $11.6 billion reduction from 2025 levels. Additional proposed cuts include $3.6 billion from the Center for Disease Control and Prevention (CDC) and $674 million from Centers for Medicare and Medicaid Services (CMS).

  • Indirect cost cap: In February 2025, reimbursement rates for indirect research costs were capped at 15% for universities and research institutions, challenging the infrastructure that supports scientific progress.

These changes signal a long-term trend: external funding requests will rise sharply as organizations seek alternative sources to sustain research and development.

The compliance challenge

An influx of grant and contribution requests brings heightened risk. Manual processes struggle to keep pace with increased volume, creating vulnerabilities in:

  • Documentation and audit trails

  • Conflict-of-interest checks

  • Regulatory compliance across jurisdictions

Without robust controls, organizations risk reputational damage, financial penalties and erosion of stakeholder trust.

Automation as a strategic tool

To navigate this complexity, life sciences companies must embrace automation. Solutions like stewardshipNOW streamline workflows, embedding compliance controls directly into the process. These automations enable:

  • Efficiency: Automated routing and approvals reduce administrative burden and accelerate decision-making.

  • Risk mitigation: Built-in compliance checks ensure adherence to regulatory standards.

  • Scalability: Systems can handle increased request volumes without compromising oversight.

By integrating technology and automation with stewardship principles, organizations can achieve a balanced approach while supporting innovation and remaining compliant.

Conclusion

The life sciences sector stands at a crossroad. Funding uncertainty and rising compliance demands require a proactive strategy rooted in stewardship and enabled by automation. Companies that act now will not only weather the storm but emerge as leaders in ethical engagement and corporate responsibility.

For more guidance, contact an experienced Baker Tilly industry practitioner about your life sciences organization today.

View additional multimedia and more ESG storytelling from Baker Tilly on 3blmedia.com.

Contact Info:
Spokesperson: Baker Tilly
Website: https://www.3blmedia.com/profiles/baker-tilly
Email: info@3blmedia.com

SOURCE: Baker Tilly



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/business-and-professional-services/strategic-stewardship-navigating-compliance-and-corporate-respon-1130276

© 2026 ACCESS Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.